Related Experiment Video

Updated: May 12, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Regorafenib: carving a niche in the crowded therapeutic landscape

Bhawna Sirohi1, Deepa Susan Philip, Shailesh V Shrikhande

  • 1Department of Medical Oncology, Tata Memorial Centre, Mumbai, India. bhawna.sirohi@btinternet.com

Expert Review of Anticancer Therapy
|April 9, 2013
PubMed

Insights

Regorafenib is an oral multikinase inhibitor effective for metastatic colorectal cancer in pretreated patients. Close monitoring is essential due to potential side effects, but biomarkers may optimize patient selection for better outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic colorectal cancer (mCRC) presents challenges in heavily pretreated populations.
  • Regorafenib, an oral multikinase inhibitor, targets tumor proliferation and vasculature.

Purpose of the Study:

  • To review the efficacy and safety of regorafenib in metastatic colorectal cancer.
  • To explore its potential in other tumor types, such as gastrointestinal stromal tumors (GIST).

Main Methods:

  • Review of clinical data and FDA approval information for regorafenib in mCRC.
  • Assessment of reported side effects and serious adverse events.
  • Consideration of biomarker data for treatment optimization.

Main Results:

  • Regorafenib demonstrated activity in heavily pretreated mCRC patients, with benefits observed across most subgroups.
  • The drug is also showing potential in other cancers like GIST.
  • Common side effects include fatigue, rash, and diarrhea; serious events involve liver toxicity and hemorrhage.

Conclusions:

  • Regorafenib is an approved treatment option for pretreated mCRC patients.
  • Careful patient monitoring is crucial due to potential adverse events.
  • Biomarker research is key to personalizing regorafenib therapy and improving patient selection.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...